128 related articles for article (PubMed ID: 12472575)
1. Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia.
Maloum K; Sutton L; Baudet S; Laurent C; Bonnemye P; Magnac C; Merle-Béral H
Br J Haematol; 2002 Dec; 119(4):970-5. PubMed ID: 12472575
[TBL] [Abstract][Full Text] [Related]
2. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
[TBL] [Abstract][Full Text] [Related]
3. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
4. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.
Vuillier F; Claisse JF; Vandenvelde C; Travade P; Magnac C; Chevret S; Desablens B; Binet JL; Dighiero G
Leuk Lymphoma; 1992 Jun; 7(3):195-204. PubMed ID: 1282428
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
8. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
Rawstron AC; Villamor N; Ritgen M; Böttcher S; Ghia P; Zehnder JL; Lozanski G; Colomer D; Moreno C; Geuna M; Evans PA; Natkunam Y; Coutre SE; Avery ED; Rassenti LZ; Kipps TJ; Caligaris-Cappio F; Kneba M; Byrd JC; Hallek MJ; Montserrat E; Hillmen P
Leukemia; 2007 May; 21(5):956-64. PubMed ID: 17361231
[TBL] [Abstract][Full Text] [Related]
9. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
[TBL] [Abstract][Full Text] [Related]
10. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.
Rawstron AC; Kennedy B; Evans PA; Davies FE; Richards SJ; Haynes AP; Russell NH; Hale G; Morgan GJ; Jack AS; Hillmen P
Blood; 2001 Jul; 98(1):29-35. PubMed ID: 11418459
[TBL] [Abstract][Full Text] [Related]
12. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL).
Magnac C; Sutton L; Cazin B; Laurent C; Binet JL; Merle-Béral H; Dighiero G; Maloum K
Hematol Cell Ther; 1999 Feb; 41(1):13-8. PubMed ID: 10193641
[TBL] [Abstract][Full Text] [Related]
13. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.
Garcia Vela J; Delgado I; Benito L; Monteserin M; Garcia Alonso L; Somolinos N; Andreu M; Oña F
Leukemia; 1999 Oct; 13(10):1501-5. PubMed ID: 10516749
[TBL] [Abstract][Full Text] [Related]
14. Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
Durrieu F; Geneviève F; Arnoulet C; Brumpt C; Capiod JC; Degenne M; Feuillard J; Garand R; Kara-Terki A; Kulhein E; Maynadié M; Ochoa-Noguera ME; Plesa A; Roussel M; Eghbali H; Truchan-Graczyk M; de Carvalho Bittencourt M; Feugier P; Béné MC
Cytometry B Clin Cytom; 2011 Nov; 80(6):346-53. PubMed ID: 21976156
[TBL] [Abstract][Full Text] [Related]
15. [The detection of minimal residual disease in patients with chronic B-cell lymphatic leukemia using patient-specified polymerase chain reaction].
Sidorova IuV; Sorokina TV; Biderman BV; Nikulina EE; Kisilichina DG; Naumova EV; Pochtar' ME; Lugovskaia SA; Ivanova VL; Kovaleva LG; Ptushkin VV; Nikitin EA; Sudarikov AB
Klin Lab Diagn; 2011 Dec; (12):22-4, 33-5. PubMed ID: 22416427
[TBL] [Abstract][Full Text] [Related]
16. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
[TBL] [Abstract][Full Text] [Related]
17. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
Böttcher S; Stilgenbauer S; Busch R; Brüggemann M; Raff T; Pott C; Fischer K; Fingerle-Rowson G; Döhner H; Hallek M; Kneba M; Ritgen M
Leukemia; 2009 Nov; 23(11):2007-17. PubMed ID: 19641522
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease assessment in chronic lymphocytic leukaemia.
Sayala HA; Rawstron AC; Hillmen P
Best Pract Res Clin Haematol; 2007 Sep; 20(3):499-512. PubMed ID: 17707836
[TBL] [Abstract][Full Text] [Related]
19. 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.
Goshaw JM; Gao Q; Wardrope J; Dogan A; Roshal M
Cytometry B Clin Cytom; 2021 Jul; 100(4):509-518. PubMed ID: 32896973
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
